HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frisoli, A. Articles by Szejnfeld, V. L. Search for Related Content PubMed PubMed Citation Articles by Frisoli, A., Jr., Articles by Szejnfeld, V. L.

The Effect of Nandrolone Decanoate on Bone Mineral Density, Muscle Mass, and Hemoglobin Levels in Elderly Women With Osteoporosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

¹ Geriatric and Gerontology Division
² Rheumatology Division, Department of Medicine, Federal University of São Paulo, Brazil.
³ Center on Aging and Health, Departments of Medicine and Epidemiology, Johns Hopkins University, Baltimore, Maryland.

Abstract

Methods. In a randomized, double-blind, placebo-controlled clinical trial, we evaluated the effect of a 2-year treatment with nandrolone decanoate (ND) on bone mineral density (BMD) of lumbar spine, femoral neck, and trochanter and on vertebral fracture rate, muscle mass, and hemoglobin levels. Sixty-five osteoporotic women older than 70 years were studied. Thirty-two patients received injections of 50 mg ND, and 33 received placebos every 3 weeks. All patients received 500 mg calcium tablets daily.

Results. Compared to baseline, ND increased the BMD of the lumbar spine (3.4% ± 6.0 and 3.7% ± 7.4; p <.05) and femoral neck (4.1% ± 7.3 and 4.7% ± 8.0; p <.05) after 1 and 2 years, respectively. The BMD of trochanter increased significantly only after the first year (4.8% ± 9.3, p <.05). Compared to the placebo group, the ND group presented with significantly increased BMD of the trochanter and neck. ND significantly reduced incidence of new vertebral fractures (21% vs 43% in the placebo group; p <.05). ND showed a significant statistical increase in lean body mass after the first (6.2% ± 5.8; p <.01) and second years (11.9% ± 29.2; p <.01). In addition, a 2-year treatment with ND significantly increased hemoglobin levels compared to baseline (14.3%; p <.01) and placebo (p <.01).

Conclusions. ND increased BMD, hemoglobin levels, and muscle mass, and reduced the vertebral fracture rate of elderly osteoporotic women.

This article has been cited by other articles:

				S. T. Page, B. T. Marck, J. M. Tolliver, and A. M. Matsumoto Tissue Selectivity of the Anabolic Steroid, 19-Nor-4-Androstenediol-3{beta},17{beta}-Diol in Male Sprague Dawley Rats: Selective Stimulation of Muscle Mass and Bone Mineral Density Relative to Prostate Mass Endocrinology, April 1, 2008; 149(4): 1987 - 1993. [Abstract] [Full Text] [PDF]